What Is MT-1? A Complete Scientific Guide

MT-1, also known as Melanotan I, is a synthetic peptide developed to mimic the naturally occurring hormone alpha-melanocyte stimulating hormone (α-MSH).

Researchers originally developed MT-1 to investigate whether increasing melanin production could provide greater protection against ultraviolet (UV) radiation and reduce the risk of sun-induced skin damage.

Unlike MT-2, MT-1 was designed to be more selective for the melanocortin-1 receptor (MC1R), the receptor primarily responsible for skin pigmentation.

A modified pharmaceutical version of MT-1, known as afamelanotide, has been developed as the prescription medicine Scenesse®, which is approved in several countries for treating adults with erythropoietic protoporphyria (EPP).

This guide explains what MT-1 is, how it works, the science behind melanin production, the available clinical evidence, and the important limitations of current research.

MT-1 quick facts

What is MT-1?

MT-1 is a laboratory-produced peptide designed to imitate alpha-melanocyte stimulating hormone (α-MSH).

Alpha-MSH is naturally produced within the body and plays an important role in:

• Skin pigmentation

• Hair pigmentation

• Response to UV exposure

• Melanin production

• Photoprotection

By activating melanocortin receptors, particularly MC1R, MT-1 encourages melanocytes to produce greater amounts of melanin.

What is alpha-MSH?

Alpha-MSH is a naturally occurring peptide hormone produced from a larger precursor protein called:

Pro-opiomelanocortin (POMC)

POMC also produces several other important hormones, including:

• ACTH

• Beta-endorphin

• Other melanocortins

Alpha-MSH primarily regulates pigmentation but also participates in appetite regulation, inflammation and energy balance.

How does MT-1 work?

MT-1 works by activating the melanocortin-1 receptor (MC1R) found on melanocytes.

Activation of MC1R triggers signalling inside the cell that increases the activity of:

Tyrosinase

Tyrosinase is the key enzyme responsible for melanin production.

As melanin production increases, skin gradually becomes darker over time.

What is MC1R?

MC1R is a receptor located mainly on melanocytes within the skin and hair follicles.

When activated it:

• Stimulates melanin production

• Promotes darker pigmentation

• Helps protect against UV damage

• Encourages production of eumelanin

Genetic differences in MC1R partly explain why some people tan easily while others burn more readily.

How is melanin produced?

Melanin is produced inside specialised cells called melanocytes.

The simplified process is:

1. Alpha-MSH activates MC1R.

2. Tyrosinase activity increases.

3. Tyrosine is converted into melanin.

4. Melanin is packaged into melanosomes.

5. Melanosomes are transferred to surrounding skin cells.

The visible result is gradual darkening of the skin.

Eumelanin vs pheomelanin

The body produces two principal forms of melanin.

• Brown to black pigment

• Better UV protection

• Associated with darker skin and hair

• More effective at absorbing ultraviolet radiation

• Red to yellow pigment

• Less effective UV protection

• More common in fair skin and red hair

• Associated with greater sun sensitivity

One goal of MT-1 research has been encouraging production of protective eumelanin.

MT-1 and UV protection

Melanin acts as the body’s natural sunscreen.

It can:

• Absorb ultraviolet radiation

• Reduce DNA damage

• Reduce oxidative stress

• Help protect skin cells from repeated UV exposure

However, increased pigmentation should not be considered a replacement for sunscreen or sensible sun protection.

MT-1 vs MT-2

Although often grouped together, MT-1 and MT-2 are different peptides.

MT-2 has broader receptor activity, whereas MT-1 was designed to focus more specifically on pigmentation pathways.

What is afamelanotide?

Afamelanotide is a modified pharmaceutical version of MT-1 developed to improve stability and duration of action.

It is marketed as:

Scenesse®

Scenesse is approved for adults with erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe pain following exposure to sunlight.

This approval does not mean that research-grade MT-1 products are approved medicines.

What is erythropoietic protoporphyria?

EPP is a rare inherited disorder in which sunlight exposure causes:

• Severe burning pain

• Swelling

• Redness

• Light intolerance

People with EPP often avoid daylight because of these symptoms.

Clinical trials found that afamelanotide increased the amount of time many patients could spend in sunlight without severe pain.

Human clinical evidence

Afamelanotide has undergone multiple human clinical trials.

Research has demonstrated benefits in appropriately selected adults with EPP by increasing pain-free sun exposure and improving quality of life.

Clinical studies have also shown increased skin pigmentation through activation of melanogenesis.

These findings relate specifically to regulated pharmaceutical afamelanotide rather than unregulated research products.

Does MT-1 cause tanning without the sun?

MT-1 stimulates melanin production.

However, UV exposure still contributes to the natural tanning process.

Many researchers believe that increased melanin production combined with responsible UV exposure produces the most noticeable pigmentation.

Intentional excessive UV exposure remains harmful regardless of pigmentation.

Does MT-1 prevent sunburn?

No.

Although increased melanin may provide additional natural protection, MT-1 should not be considered a substitute for:

• Sunscreen

• Protective clothing

• Limiting UV exposure

Sunburn, DNA damage and skin ageing can still occur.

MT-1 and skin cancer

One of the original scientific interests in MT-1 was whether increasing protective eumelanin could reduce UV-induced DNA damage.

Research has shown improvements in pigmentation and photoprotection markers.

However, MT-1 is not approved to prevent skin cancer.

People should continue routine skin examinations and seek medical advice regarding changing moles or suspicious skin lesions.

Side effects

Reported adverse effects with afamelanotide have included:

• Headache

• Nausea

• Fatigue

• Injection-site reactions

• Increased pigmentation

• Freckling

Some individuals also experience darkening of existing moles or freckles.

Any changing skin lesion should be assessed by a healthcare professional.

Safety considerations

Important considerations include:

• MT-1 is not approved as a cosmetic tanning medicine.

• Human safety data relate primarily to pharmaceutical afamelanotide.

• Long-term effects of unregulated research products remain uncertain.

• Product quality may vary significantly.

Pregnancy and breastfeeding

There is insufficient evidence to establish the safety of MT-1 during:

• Pregnancy

• Breastfeeding

It should not be assumed to be safe in either situation.

Common myths

Fact: They are different peptides with different receptor profiles.

Fact: It does not.

Fact: Individual responses vary considerably.

Fact: It is not.

Fact: Regulatory approval applies only to the authorised pharmaceutical product.

Frequently asked questions

Yes.

Afamelanotide is the pharmaceutical analogue developed from MT-1.

Primarily MC1R.

Yes, through activation of melanocytes.

It is a synthetic analogue of the natural hormone alpha-MSH.

Research suggests increased eumelanin production is one of its primary actions.

It stimulates melanin production, although UV exposure remains part of normal tanning biology.

Only afamelanotide (Scenesse®) is approved for EPP.

No.

No.

No.

Yes, increased pigmentation may include freckles and existing moles.

Pigmentation generally fades over time after treatment stops.

No.

Its activity is more selective than MT-2 and appetite effects are not its primary research focus.

Research in context

Human evidence supports that pharmaceutical afamelanotide increases pigmentation and improves sunlight tolerance in adults with EPP.

Laboratory research suggests enhanced melanin production may improve natural photoprotection.

Researchers have not established:

• Long-term cosmetic safety

• Safety of unregulated MT-1 products

• Effectiveness for preventing skin cancer

• Long-term outcomes outside approved medical use

Key takeaways

MT-1 is a synthetic analogue of alpha-MSH designed to increase melanin production through activation of MC1R.

It differs from MT-2 by having greater selectivity for pigmentation pathways.

A pharmaceutical form, afamelanotide (Scenesse®), is approved for adults with erythropoietic protoporphyria.

This approval does not apply to research-grade MT-1 products.

MT-1 should not be regarded as a replacement for sunscreen, nor as an approved cosmetic tanning medicine.

Glossary

Afamelanotide: Pharmaceutical analogue of MT-1.

Alpha-MSH: Alpha-melanocyte stimulating hormone.

EPP: Erythropoietic protoporphyria.

Eumelanin: Dark protective melanin pigment.

MC1R: Melanocortin-1 receptor.

Melanin: Pigment responsible for skin, hair and eye colour.

Melanocyte: Cell responsible for producing melanin.

Pheomelanin: Red-yellow melanin pigment.

POMC: Pro-opiomelanocortin precursor protein.

Tyrosinase: Enzyme required for melanin synthesis.

This article is provided for educational purposes only.

It is not intended to diagnose, treat or prevent disease or replace advice from a qualified healthcare professional.

MT-1 is a research peptide. Although afamelanotide is an authorised medicine for the treatment of erythropoietic protoporphyria in specific clinical settings, this approval does not apply to research-grade MT-1 products.

Research compounds should not be assumed to have the same quality, safety or effectiveness as regulated pharmaceutical medicines.